Floatz logo

Lapelga

Engagement, Patient

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Engagement, Patient cohort.

Same molecule, other indications

Lapelga is also rated in:

Febrile NeutropeniaDormant
B
Indicative ·
60 / 100
View asset →
lymphomaDormant
CCC
Indicative ·
52 / 100
View asset →
plasma cell myelomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →